endpts.com·Jun 4, 2026
Otsuka Pharmaceutical has presented new evidence to support its application for full approval of the monoclonal antibody Voyxact, aimed at treating immunoglobulin A nephropathy (IgAN).
Otsuka Pharmaceutical is leveraging new evidence to seek full FDA approval for its monoclonal antibody, Voyxact, targeting a chronic autoimmune condition. This indicates a potential opportunity for investment or partnerships in the autoimmune treatment space, especially for those interested in the development and regulatory approval process of innovative biologics.